Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 112 clinical trials
A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer

The phase 1 study is an open label, multi-center, non-randomized, dose escalation and expansion study designed to assess the safety, tolerability, and immunogenicity of IMU-201(PD1-Vaxx) as monotherapy in patients with PD-L1 expressing non-small cell lung cancer (NSCLC).

adenocarcinoma
platelet count
lung carcinoma
cancer
carcinoma
  • 7 views
  • 23 Mar, 2022
  • 6 locations
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC

. The addition of bevacizumab to carboplatin and paclitaxel in first-line treatment of non-squamous NSCLC showed improved survival compared to carboplatin and paclitaxel alone, 12.3 vs. 10.3

  • 0 views
  • 23 Mar, 2022
  • 1 location
Evaluation of the Feasibility and Clinical Relevance of Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer (LIBELULE)

Lung cancer is diagnosed at metastatic stage in 60% of the cases. For these patients, first-line treatment is based on histology and molecular characterization of non-squamous non-small cell

LKB1
cancer
erbb2
cancer treatment
EGFR
  • 1 views
  • 09 Feb, 2022
  • 15 locations
Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies

The purpose of the study is to determine to evaluate safety and tolerability of CPL304110 when administered once daily to adults with advanced solid malignancies.

formalin-fixed paraffin-embedded
bladder tumor
bladder cancer
sarcoma
cancer
  • 32 views
  • 14 Apr, 2022
  • 4 locations
Research Trial to Study Safety of GEN1047 (DuoBody®-CD3xB7H4) in Participants With Malignant Solid Tumors

The drug that will be investigated in the study is an antibody, GEN1047. Since this is the first study of GEN1047 in humans, the main purpose is to evaluate safety. Besides safety, the study will determine the recommended GEN1047 dose to be tested in a larger group of participants and …

breast cancer
cancer antigen 125
cancer
carcinoma
cancer of the ovary
  • 1 views
  • 09 Aug, 2022
  • 6 locations
Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC

advanced or metastatic squamous non-small cell lung cancer. t the same time, Tislelizumab initial efficacy in patients with extensive small-cell lung cancr.Rational-206 study is a phase Ⅱ multi-cohort

chemoradiotherapy
platinum-based chemotherapy
anlotinib
cancer chemotherapy
Accepts healthy volunteers
  • 0 views
  • 14 Jul, 2022
  • 1 location
Sintilimab Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

This is a single-arm, prospective, exploratory clinical study aiming to evaluate the efficacy and safety profile of sintilimab combined with anlotinib hydrochloride and platinum-containing dual-agent chemotherapy regimens in advanced or metastatic NSCLC as first-line treatment. Totally 40 patients with negative driver genes (20 patients of squamous cell carcinoma, 20 patients …

  • 0 views
  • 18 Aug, 2021
  • 1 location
PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 50 %

PERSEE is a French national phase 3 academic study comparing the chemotherapy-pembrolizumab combination to pembrolizumab alone as a first-line treatment for advanced NSCLC molecularly defined by a PDL1 expression 50% of tumour cells and no EGFR mutations or ALK rearrangement. The main hypothesis is the superiority of the chemo-immunotherapy combination …

  • 0 views
  • 18 Mar, 2021
  • 31 locations
Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage NSCLC

The purpose of this study is to evaluate the safety and efficacy of Camrelizumab in combination with platinum doublet neoadjuvant chemotherapy before surgery [neoadjuvant phase], followed by Camrelizumab alone after surgery [adjuvant phase] in participants with unresectable stage III non-small cell lung cancer.

lung carcinoma
pemetrexed
stage iii non-small cell lung cancer
platinum doublet
paclitaxel
  • 0 views
  • 09 Sep, 2021
  • 1 location
Tislelizumab in Addition to BACE in Patients With NSCLC

This is a single-arm phase II trial to determine the efficacy and safety of Tislelizumab in addition to bronchial arterial chemoembolization in stage III-Ⅳ NSCLC patients who failed, refused or ineligible to receive standard treatments.

chemoradiotherapy
cancer chemotherapy
  • 0 views
  • 21 Mar, 2022
  • 1 location